Drug Combination Details
| General Information of the Combination (ID: C35852) | |||||
|---|---|---|---|---|---|
| Name | Taxifolin NP Info | + | Dapagliflozin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Healthy individual
[ICD-11: N.A.]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | GABPA | Molecule Info | ||
| Up-regulation | Expression | JNK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TLR4 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Male rats were used to establish colistin-induced nephrotoxicity animal model in this study. | |||||
| Experimental
Result(s) |
Combined use of taxifolin and dapagliflozin may confer a therapeutic tool for attenuation of colistin-induced nephrotoxicity. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Effect of taxifolin/dapagliflozin combination on colistin-induced nephrotoxicity in rats. Hum Exp Toxicol. 2021 Apr 22;9603271211010906. | |||
